glp-1 with medicaid Coverage of and Spending on GLP-1s Today we're announcing the CMS

There are no clinical trials on this patch format, no data testing this ingredient combo, and no human studies showing increased GLP-1 levels from this approach

In early 2026, Roche paid $100 million to secure a non-exclusive patent licence from Structures subsidiary Gasherbrum Bio, covering intellectual property relevant to CT-996, the oral GLP-1 compound Roche acquired through its $2.7 billion buyout of Carmot Therapeutics in late 2023

This is an important stage, as incomplete or inconsistent data will stall acceptance

Most patients begin noticing a decrease in appetite and improved control over cravings within the first one to two weeks of starting GLP-1 treatment

The most consistently observed adverse events in clinical trials to date involve gastrointestinal symptoms

This blog provides a snapshot of the key findings in the most recent report